Muscarinic Receptors: Their Roles in Disorders of the Central Nervous System and Potential as Therapeutic Targets

Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial

(2010) Wayne C. Drevets et al.   BIOLOGICAL PSYCHIATRY

Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease

(2010) Cassia R. Overk et al.   JOURNAL OF CHEMICAL NEUROANATOMY

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in Men

(2010) Maura L Furey et al.   NEUROPSYCHOPHARMACOLOGY

Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2 ) with nicotine addiction

(2009) A. Mobascher et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Cholinergic Functioning in Stimulant Addiction

(2009) Mehmet Sofuoglu et al.   CNS DRUGS

Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder

(2009) S. Cohen-Woods et al.   HUMAN MOLECULAR GENETICS

Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-TrifluoromethoxyN-Benzyl Isatins

(2009) Thomas M. Bridges et al.   JOURNAL OF MEDICINAL CHEMISTRY

Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study

(2009) U. Ehrt et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning

(2009) J. K. Shirey et al.   JOURNAL OF NEUROSCIENCE

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

(2009) Stefania Risso Bradley et al.   NEUROPHARMACOLOGY

Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gαq/11 Coupling in a Schizophrenia Endophenotype

(2009) Hasib Salah-Uddin et al.   NEUROPSYCHOPHARMACOLOGY

Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties

(2009) Katie Leach et al.   NEUROPSYCHOPHARMACOLOGY

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

(2008) Anantha Shekhar et al.   AMERICAN JOURNAL OF PSYCHIATRY

Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M₁ receptor agonist, AC-260584.

(2008) Kimberly E. Vanover et al.   BEHAVIORAL NEUROSCIENCE

Diphenidol-related diamines as novel muscarinic M4 receptor antagonists

(2008) Lucilla Varoli et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Characterization of a CNS penetrant, selective M1muscarinic receptor agonist, 77-LH-28-1

(2008) C J Langmead et al.   BRITISH JOURNAL OF PHARMACOLOGY

Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans

(2008) I Wessler et al.   BRITISH JOURNAL OF PHARMACOLOGY

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice

(2008) Marie L. Woolley et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Role of the cholinergic system in the pathology and treatment of schizophrenia

(2008) Elizabeth Scarr et al.   Expert Review of Neurotherapeutics

Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects

(2008) A.S. Gibbons et al.   JOURNAL OF AFFECTIVE DISORDERS

Muscarinic acetylcholine receptors in macaque V1 are most frequently expressed by parvalbumin-immunoreactive neurons

(2008) Anita A. Disney et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

(2008) C. K. Jones et al.   JOURNAL OF NEUROSCIENCE

Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats

(2008) A. E. Brady et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia

(2008) E Scarr et al.   MOLECULAR PSYCHIATRY

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

(2008) W. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer’s disease patients with psychosis

(2008) S. W. Y. Tsang et al.   PSYCHOPHARMACOLOGY

Muscarinic acetylcholine receptors as CNS drug targets

(2007) Christopher J. Langmead et al.   PHARMACOLOGY & THERAPEUTICS

The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers

(2007) R. De La Garza et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR